ProFuse Technology—an Israeli startup best-known for media supplements that increase the speed and efficiency of muscle tissue formation in cultivated meat—has launched a high throughput screening platform for skeletal muscle related drug discovery. Read more...
Read MoreKNOXVILLE, Tenn. — In a commercialization landmark for the fusion industry, Type One Energy entered into a Cooperative Agreement with the Tennessee Valley Authority (TVA) to jointly develop plans for a potential TVA fusion power plant project in the Tennessee Valley region using Type One Energy stellarator fusion power technology. The 350 MWe fusion pilot power plant, named Infinity Two, offers a complementary source of base load electrical generation for the region as early as the mid-2030s. It has the potential to repurpose retired TVA fossil fuel power plant infrastructure in addition to being deployed onto greenfield sites in support of energy security and reliability. Read...
Read MoreNEW YORK, Feb. 11, 2025 /PRNewswire/ — DailyPay, a leading worktech platform powering daily opportunities for workers and their employers, has appointed Deepa Subramanian as Chief Financial Officer. Ken Brause, who served as Chief Financial Officer since November 2023 has been appointed Chief Administrative Officer. Both will report to DailyPay Chief Executive Officer Stacy Greiner and serve as members of her Executive Leadership Team. Read...
Read MoreDEVENS, Mass. and KNOXVILLE, Tenn., Feb. 11, 2025 /PRNewswire/ — Commonwealth Fusion Systems (CFS) and Type One Energy announced an agreement that gives Type One Energy an exclusive license to use CFS’ groundbreaking high-temperature superconducting (HTS) cable technology in the development of its own proprietary stellarator fusion magnets. The agreement also gives Type One Energy the benefit of the experience CFS has in manufacturing the world’s most powerful HTS fusion magnets. Read...
Read MoreBOSTON–(BUSINESS WIRE)–Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today its latest strategic collaboration with Pfizer Inc., to develop a new platform that could enhance Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies. Under the terms of the collaboration, Alloy will receive an upfront payment from Pfizer and will be eligible for pre-specified preclinical to commercial milestones on products originating from the newly developed platform. Read...
Read More
